SciELO - Scientific Electronic Library Online

 
vol.39 issue2Glymphatic system: Anatomo-physiological principles and their clinical implicationsSubacute combined degeneration author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Acta Neurológica Colombiana

Print version ISSN 0120-8748On-line version ISSN 2422-4022

Abstract

MARTINEZ, José David et al. Biotherapeutic medicines: use of botulinum toxins in the era of biosimilars. Acta Neurol Colomb. [online]. 2023, vol.39, n.2, e9.  Epub Nov 02, 2023. ISSN 0120-8748.  https://doi.org/10.22379/anc.v39i2.867.

Introduction:

Botulinum toxins are biotherapeutic drugs with great applications in the field of neurology such as headache and abnormal movements. Due to the medical importance and the increase in therapeutic indications of botulinum toxin, this article aims to clarify the basic terminology regarding the nature of this drug, the structural differences with conventional drugs and important aspects in relation to its biological potency and immunogenicity in order to understand the potential differences between the available toxins and conceptualize regarding the non-interchangeability or substitution of one toxin for another.

Materials and methods:

Non-systematic review as recommended in the Scale for the Verification of Narrative Review Articles (SANRA).

Conclusions:

Biological drugs are not interchangeable with each other, even if they demonstrate bioequi-valence. They cannot be evaluated as interchangeable generic drugs because they are biologics. There are no head-to-head comparative studies. They are different due to the individual manufacturing process.

Keywords : Biosimilar pharmaceuticals; Inmunogenicity; Interchange of drugs; Botulinum toxins; type A.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )